On November 30, 2023, two Phase I clinical trials of ZHB107-108 sublingual tablets, a new drug originally developed by ZONHONBIO with fully independent intellectual property rights at home and abroad, were formally initiated at the Jiangsu Province Hospital (the First Affiliated Hospital with Nanjing Medical University).

These two Phase I clinical studies, “Safety Study of ZHB107-108 Sublingual Tablets in Adult Patients with House Dust Mite Allergic Rhinitis” and "Safety Study of ZHB107-108 Sublingual Tablets in Adult Patients with House Dust Mite Allergic Asthma”, initiated by ZONHONBIO as a sponsor, were conducted by Prof. Cheng Lei, Chairman of the Division of Allergy of the Chinese Medical Association, Director of the Department of Otorhinolaryngology and Director of Allergy Diagnostic and Treatment Center of the Jiangsu Province Hospital, who acted as the principal investigator, to assess the tolerability and safety of ZHB107-108 Sublingual Tablets after their administration to the subjects.

Specific immunotherapy, also known as desensitization therapy, is currently the only therapeutic modality that is considered to have the potential to alter the course of allergic diseases. ZHB107-108 is a new sublingual tablet desensitization therapy formulation (with controllable dosage, good storage stability, and convenient dosing), which is taken sublingually, to induce immune tolerance, thereby altering the natural course of allergic diseases and improving the condition of patients in a sustained method, offering a new solution for House Dust Mite allergy patients to improve their quality of life.